Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors

Sheetal Mehta Kircher*, Halla S Nimeiri, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. Targeting angiogenesis has been achieved by several mechanisms in colorectal cancer, including use of antiangiogenic small molecule tyrosine kinase inhibitors (TKIs). There have been many attempts and failures to prove efficacy of TKIs in the treatment of colorectal cancer including sorafenib, sunitinib, vatalanib, and tivozanib. Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.

Original languageEnglish (US)
Pages (from-to)182-189
Number of pages8
JournalCancer Journal (United States)
Volume22
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

Protein-Tyrosine Kinases
Colorectal Neoplasms
Vascular Endothelial Growth Factor Receptor-3
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Angiogenesis Inhibitors
Receptor Protein-Tyrosine Kinases
Neoplasms
regorafenib

Keywords

  • Angiogenesis inhibitors
  • Colorectal neoplasms
  • Drug therapy
  • Protein-tyrosine kinases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{f638c38b7547409aa216a8d97b08b842,
title = "Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors",
abstract = "Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. Targeting angiogenesis has been achieved by several mechanisms in colorectal cancer, including use of antiangiogenic small molecule tyrosine kinase inhibitors (TKIs). There have been many attempts and failures to prove efficacy of TKIs in the treatment of colorectal cancer including sorafenib, sunitinib, vatalanib, and tivozanib. Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.",
keywords = "Angiogenesis inhibitors, Colorectal neoplasms, Drug therapy, Protein-tyrosine kinases",
author = "Kircher, {Sheetal Mehta} and Nimeiri, {Halla S} and {Benson III}, {Al B}",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/PPO.0000000000000192",
language = "English (US)",
volume = "22",
pages = "182--189",
journal = "Cancer Journal",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "3",

}

Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors. / Kircher, Sheetal Mehta; Nimeiri, Halla S; Benson III, Al B.

In: Cancer Journal (United States), Vol. 22, No. 3, 01.01.2016, p. 182-189.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors

AU - Kircher, Sheetal Mehta

AU - Nimeiri, Halla S

AU - Benson III, Al B

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. Targeting angiogenesis has been achieved by several mechanisms in colorectal cancer, including use of antiangiogenic small molecule tyrosine kinase inhibitors (TKIs). There have been many attempts and failures to prove efficacy of TKIs in the treatment of colorectal cancer including sorafenib, sunitinib, vatalanib, and tivozanib. Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.

AB - Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. Targeting angiogenesis has been achieved by several mechanisms in colorectal cancer, including use of antiangiogenic small molecule tyrosine kinase inhibitors (TKIs). There have been many attempts and failures to prove efficacy of TKIs in the treatment of colorectal cancer including sorafenib, sunitinib, vatalanib, and tivozanib. Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.

KW - Angiogenesis inhibitors

KW - Colorectal neoplasms

KW - Drug therapy

KW - Protein-tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=84978187241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978187241&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000192

DO - 10.1097/PPO.0000000000000192

M3 - Review article

C2 - 27341596

AN - SCOPUS:84978187241

VL - 22

SP - 182

EP - 189

JO - Cancer Journal

JF - Cancer Journal

SN - 0765-7846

IS - 3

ER -